Selective induction of cancer cell death by VDAC1-based peptides and their potential use in cancer therapy

Area of Science:

• Mitochondrial biology
• Cancer research
• Drug development

Background:

• Mitochondrial VDAC1 plays a crucial role in cellular energy and apoptosis, making it a target in cancer development.
• Cancer cells reprogram metabolism and evade apoptosis, hallmarks influenced by VDAC1.
• Previous VDAC1-derived peptides showed promise in inducing cancer cell death.

Purpose of the Study:

• To evaluate the sensitivity of diverse cancer cell lines to VDAC1-based peptide-induced apoptosis.
• To develop improved VDAC1-based peptides with enhanced targeting, selectivity, and stability.
• To investigate the therapeutic potential of VDAC1-based peptides in preclinical cancer models.

Main Methods:

• Testing VDAC1-based peptides on genetically characterized cancer and noncancerous cell lines.
• Designing and synthesizing novel VDAC1-based peptides, including R-Tf-D-LP4 with a transferrin receptor targeting sequence.
• Assessing peptide mechanisms, including hexokinase detachment and interference with anti-apoptotic proteins.
• Evaluating R-Tf-D-LP4 efficacy in xenograft models of glioblastoma, lung, and breast cancer.

Main Results:

• Cancer cell lines showed significant sensitivity to VDAC1-based peptides, while noncancerous cells were less affected.
• The novel peptide R-Tf-D-LP4 demonstrated improved targeting and efficacy.
• VDAC1-based peptides induce apoptosis by disrupting cellular energy homeostasis and interfering with anti-apoptotic proteins.
• R-Tf-D-LP4 significantly inhibited tumor growth and induced cancer cell death, including in cancer stem cells, in vivo.

Conclusions:

• VDAC1-based peptides represent a novel therapeutic strategy for cancer.
• Targeted VDAC1 peptides, like R-Tf-D-LP4, show significant potential for cancer treatment.
• These peptides offer a new conceptual framework for developing innovative cancer therapies.